Global Force-of-Infection Trends for Human Taenia solium Taeniasis/Cysticercosis

- 3
- 4 Matthew A. Dixon^{1,2,3*}, Peter Winskill², Wendy E. Harrison^{3,†}, Charles Whittaker^{1,2}, Veronika
- 5 Schmidt^{4,5}, Astrid Carolina Flórez Sánchez⁶, Zulma M. Cucunubá^{1,2,§}, Agnes U. Edia-Asuke⁷, Martin
- 6 Walker⁸, Maria-Gloria Basáñez^{1,2}
- 7 * Corresponding author: <u>m.dixon15@imperial.ac.uk</u>
- 8 1 Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease
- 9 Research (LCNTDR), Faculty of Medicine, School of Public Health, Imperial College London, London
- 10 W2 1PG, UK
- 11 2 MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology,
- 12 Faculty of Medicine, School of Public Health, Imperial College London, London W2 1PG, UK
- 13 3 SCI Foundation, Edinburgh House, 170 Kennington Lane, London, SE11 5DP
- 14 4 Department of Neurology, Center for Global Health, Technical University Munich (TUM), Munich,
- 15 Germany
- 16 5 Centre for Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway
- 17 6 Grupo de Parasitología, Instituto Nacional de Salud, Bogotá, Colombia
- 18 7 Ahmadu Bello University, 810211, Zaria, Nigeria
- 19 8 Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical
- 20 Disease Research (LCNTDR), Royal Veterinary College, Hatfield AL9 7TA, UK
- 21 § Present address: Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina,
- 22 Pontificia Universidad Javeriana, Bogotá, Colombia
- 23 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

Infection by *Taenia solium* poses a major burden across endemic countries. The World Health Organization (WHO) 2021–2030 Neglected Tropical Diseases roadmap has proposed that 30% of endemic countries achieve intensified *T. solium* control in hyperendemic areas by 2030. Understanding geographical variation in age-prevalence profiles and force-of-infection (FoI) estimates will inform intervention designs across settings.

Human taeniasis (HTT) and human cysticercosis (HCC) age-prevalence data from 16 studies in Latin America, Africa and Asia were extracted through a systematic review. Catalytic models, incorporating diagnostic performance uncertainty, were fitted to the data using Bayesian methods, to estimate rates of antibody (Ab)-seroconversion, infection acquisition and Ab-seroreversion or infection loss. HCC Fol and Ab-seroreversion rates were also estimated across 23 departments in Colombia from 28,100 individuals.

Across settings, there was extensive variation in all-ages seroprevalence. Evidence for Abseroreversion or infection loss was found in most settings for both HTT and HCC and for HCC Abseroreversion in Colombia. The average duration until humans became Ab-seropositive/infected decreased as all-age (sero)prevalence increased. There was no clear relationship between the average duration humans remain Ab-seropositive and all-age seroprevalence.

42 Marked geographical heterogeneity in *T. solium* transmission rates indicate the need for setting43 specific intervention strategies to achieve the WHO goals.

45 Introduction

46 The zoonotic cestode Taenia solium poses a substantial public health and economic challenge. 47 Globally, T. solium is ranked as the foodborne parasitic infection contributing the highest number 48 of disability-adjusted life-years (DALYs), an estimated 2.78 million DALYs in 2010 (Havelaar et al., 49 2015). Control and elimination of *T. solium* requires a One Health approach (Thomas et al., 2019; 50 Braae et al., 2019) due to its complex multi-host life-cycle, involving infection with larval-stage 51 cysticerci in the intermediate pig host (porcine cysticercosis, or PCC), infective stages (eggs) in the 52 environment, and taeniasis (infection with the adult worm) in the definitive human host (human 53 taeniasis, or HTT). When humans ingest T. solium eggs, establishment of cysticerci (human 54 cysticercosis, or HCC) in the central nervous system results in neurocysticercosis (NCC). 55 Neurocysticercosis is responsible for the major health burden associated with T. solium, causing 56 approximately one third of epilepsy/seizure disorders in endemic settings (Gripper and Welburn, 57 2017).

58 Current interventions target PCC through mass treatment of pigs with oxfendazole and their vaccination with TSOL18, and HTT through mass treatment of humans with praziguantel or 59 60 niclosamide. These control strategies have proven efficacious in field studies (de Coster et al., 2018; Dixon et al., 2021), but to date no large-scale interventions have been rolled out as part of national 61 62 Neglected Tropical Disease (NTD) programmes, and therefore their impact alone or in combination 63 in different epidemiological settings remains poorly understood and/or modelled (CystiTeam, 64 2019). The milestones proposed in the new World Health Organization (WHO) NTD 2021–2030 65 roadmap (World Health Organization, 2020) focus on achieving intensified control in hyperendemic areas of 17 (27%) endemic countries. However, endemicity levels for T. solium have not been 66 defined in terms of infection indicators and there exist limited data on the geographical distribution 67 of T. solium prevalence at national scales. For other NTDs, pre-intervention levels of endemicity 68 69 (according to infection prevalence, intensity, incidence or morbi-mortality) determine the

70 magnitude, duration and likely success of control efforts (NTD Modelling Consortium 71 Onchocerciasis Group, 2019). Therefore, successful *T. solium* intervention strategies will require 72 tailoring to local epidemiological and socio-economic conditions that determine the intensity of 73 transmission and will likely be informed by age- and/or sex-dependent contact rates and mixing 74 patterns in endemic settings (Dixon et al., 2021; CystiTeam, 2019, Welburn et al., 2015).

Global patterns in transmission rates have recently been explored for PCC by assessing the forceof-infection (FoI; the per-capita rate of infection acquisition) according to proposed endemicity levels (overall (sero)prevalence) and geography (Dixon et al., 2020). Estimates of antibody (Ab) and antigen (Ag) seroconversion (and seroreversion rates) for HCC have also been estimated from a small number of longitudinal surveys in Burkina Faso (Dermauw et al., 2018), Peru (Garcia et al., 2001)], Ecuador (Coral-Almeida et al., 2014) and Zambia (Mwape et al., 2013), demonstrating substantial geographic variation.

82 Age-prevalence profiles are not only useful for estimating FoI and (sero)reversion rates, but also to 83 provide insight into processes driving epidemiological dynamics, such as immunological responses 84 or heterogeneity in exposure which may explain abrupt changes in HCC seropositivity in older 85 individuals or distinct prevalence peaks in younger ages for HTT prevalence, as observed in the 86 Democratic Republic of the Congo (DRC) (Kanobana et al., 2011; Madinga et al., 2017). Specific age-87 prevalence profiles may also provide insight into whether age-targeted interventions may be 88 appropriate in certain settings. This study, therefore, and for the first time systematically collates 89 and reviews all HTT and HCC age-(sero)prevalence data available from the literature and from collaborators, and uses simple and reversible catalytic models to estimate the FoI and Ab-90 91 seroreversion/infection loss rates from cross-sectional surveys. The results improve our 92 understanding of global variation in the epidemiology of T. solium and provide estimates of 93 transmission rates, crucial for guiding the design of interventions. In addition, a country profile of

94 Fol estimates is presented at the sub-national level for Colombia to exemplify how detailed Fol

95 analyses can help understand local epidemiological patterns.

96

97 Results

98 Systematic review and study selection

99 After title, abstract and full-text eligibility screening of 236 studies initially identified (01/11/2014 100 to 02/10/2019), and 11 studies included in the Coral-Almeida et al. (2015) literature review, a total 101 of 16 studies were included in the analysis (PRISMA flowchart; Supplementary File 1: 102 Supplementary Figure S1), originating from South America (n = 4), Africa (n = 8) and Asia (n = 4)103 (Supplementary File 1: Supplementary Figure S2) and split by *n* = 4 HTT and *n* = 15 HCC surveys (full 104 details in Supplementary File 1: Supplementary Table S1). Total sample sizes were 6,653 individuals 105 (range 576–4,599; with individual age range of <1 to 96 years) across HTT surveys, which included 106 three copro-Ag-based surveys and one Ab-based survey; 34,124 (125-29,360; cross-study age 107 range of <1 to 95 years) across HCC-Ab surveys, and 12,934 (905–4,993; cross-study age range of 108 <1 to 96 years) across HCC-Ag surveys. Observed (sero)prevalence ranged from 4.5% to 23.4% (95% 109 confidence interval (CI) range: 3.0%–24.6%) for HTT surveys, 0.5%–38.7% (0.1%–41.6%) across 110 HCC-Ab surveys, and 0.7%–21.7% (0.5%–24.5%) across HCC-Ag surveys.

111 Catalytic models (Figure 1; full details in Material and methods) were fitted to the thus extracted 112 (sero)prevalence data using a Bayesian framework that integrates uncertainty in diagnostic 113 sensitivity and specificity from prior (published) information (Supplementary File 1: Supplementary 114 Table S1). The FoI parameters of acquisition (λ) and reversion/loss (ρ) (for antibody datasets: λ_{sero} 115 and ρ_{sero} ; for antigen datasets: λ_{inf} and ρ_{inf}) were estimated for each dataset. The deviance 116 information criterion (DIC) (Spiegelhalter et al., 2002) was used to compare individually- and 117 jointly-fitted catalytic models.

118 We defined hyperendemic transmission settings as those with all-age *observed* HTT 119 (sero)prevalence of \geq 3% and all-age *observed* HCC (sero)prevalence of \geq 6%. Studies with 120 (sero)prevalence values below these were defined as endemic transmission settings. These 121 putative endemicity definitions were defined following a literature review of studies referring to 122 "hyper" or "highly" endemic settings (Supplementary File 1: Supplementary Table S2).

123 [Figure 1 here]

124 Figure 1. Simple and reversible catalytic model structure and equations fitted to data on the age 125 (a)-specific (sero)prevalence (p(a)) data, where λ is the force-of-infection (rate of antibody (Ab)-126 seroconversion or infection acquisition) and ρ the rate of Ab-seroreversion or infection loss. The 127 general mathematical form of the catalytic models (equations 1a to 1d) fitted to the human 128 taeniasis (HTT)/human cysticercosis (HCC) Ab, HCC Ag and HTT copro-Ag prevalence datasets to 129 estimate the prevalence (p) at human age (a). The saturating (sero) prevalence is given by $\lambda/(\lambda + \rho)$ 130 which for the simple model is 100%, if the humans lived sufficiently long. The accompanying tables 131 provide information on the definitions of the catalytic model parameters depending on the 132 diagnostic method. Presence of adult tapeworm excretory-secretory products indicative of active or past HTT infection, as outlined by Lightowlers et al. 2016a. 133

134

135 Global human taeniasis (HTT) copro-antigen and antibody seroprevalence

Table 1 compares models fitted either including (reversible model) or excluding (simple model) HTT infection loss (when fitted to copro-Ag ELISA using the Allan et al. (1990) protocol datasets, except in Gomes et al. (2002) where a protocol is not specified) or Ab-seroreversion. For the copro-Ag ELISA datasets (to which models were jointly fitted to yield a single sensitivity and specificity posterior), DIC scores were similar (within one unit) between models with and without infection loss (Table 1 and Figure 2a), indicating limited information to differentiate between model fits.

142 The copro-Ag ELISA datasets (Gomes et al., 2002; Mwape et al., 2012) were found in hyperendemic 143 settings (all-age HTT (sero)prevalence ≥3%) in Zambia (6.3%) (Mwape et al., 2012) and Brazil (4.5%) 144 (Gomes et al., 2002). For the models independently fitted to the single dataset in Lao People's 145 Democratic Republic (Lao PDR) (Holt et al., 2016) using the rES33-immunoblot (Wilkin et al., 1999) 146 and found in an endemic setting (all-age HTT antibody seroprevalence of 2.5%), there was also 147 limited information to differentiate between model fits, with DIC scores similar (within one unit) 148 between the model with and without Ab-seroconversion (Table 1 and Figure 2b). The FoI (λ_{sero}) for 149 the best-fit model to the rES33-immunoblot antibody dataset in Lao PDR (Holt et al., 2016), suggested a very low HTT Ab-seroconversion rate of 0.00046 year⁻¹ (all model fits and DIC scores 150 151 in Supplementary File 1: Supplementary File Table S3). The Madinga et al. (2017) dataset in the 152 DRC was omitted from the models jointly fitted across copro-Ag ELISA datasets, due to difficulty 153 fitting catalytic models to such a distinct age-prevalence profile with a marked peak in early ages 154 (see Discussion).

155 [Figure 2 here]

156 Figure 2. The relationship between human taeniasis copro-antigen (Copro-Ag) and antibody 157 (sero)prevalence and human age (in years) for each dataset. Human taeniasis (HTT) infection 158 acquisition (simple) or acquisition with infection loss (reversible) catalytic models jointly fitted to 159 multiple datasets (where single diagnostic sensitivity and specificity values were estimated; dataset-160 specific λ and ρ estimates were obtained) in a); HTT antibody (Ab)-seroconversion (simple) or Ab-161 seroconversion with Ab-seroreversion to a single dataset in **b**). 95% confidence intervals associated 162 with observed (sero)prevalence point estimates are also presented. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the parameter posterior distributions used 163 to construct predicted (all age) (sero)prevalence curves and associated 95% Bayesian credible 164 165 intervals (BCIs). Best-fitting model selected by deviance information criterion (DIC); both models 166 presented if difference between DIC < 2 (both models have similar support based on the data); a

- 167 difference > 10 units indicates that the models are significantly different and therefore only superior
- 168 fitting model (lowest DIC) is presented). The non-zero predicted (sero)prevalence at age 0 is due to
- less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-(sero)prevalence
- 170 data-points are calculated by the Clopper-Pearson exact method.

Table 1. (Sero)prevalence and parameter posterior estimates for the best-fit catalytic models fitted to human taeniasis (antibody and antigen) age-(sero)prevalence datasets (ordered by decreasing all-age (sero)prevalence).

Dataset	All-age observed (sero)- prevalence (%) (95% Cl)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	λ = infection acquisition (λ_{inf}) or Ab- seroconversio n (λ_{sero}) rate, year ⁻¹ (95% BCI)**	ρ = infection loss (ρ_{inf}) or Ab- seroreversion (ρ_{sero}) rate, year ⁻¹ (95% BCI)**	
Models jointly	Models jointly fitted to multiple datasets (Copro-Ag ELISA) ^a						
Mwape et al. 2012 Antigen [†] Gomes et al. 2002	6.32 (4.65 – 8.37) 4.51 (2.97 – 6.54)	Reversible ^b	0.824 (0.533 – 0.972)	0.959 (0.941 – 0.976)	0.021 (0.0038 – 0.062) 0.0096 (0.00072 –	0.768 (0.362 – 0.991) 0.731 (0.379 – 0.978)	
Antigen ⁺⁺					0.032)		
Models independently fitted to single datasets (rES33-immunoblot) ^c							
Holt et al. 2016 Antibody	2.49 (1.51 – 3.87)	Simple ^d	0.982 (0.959 – 0.996)	0.992 (0.978 – 0.999)	0.00044 (0.000103 – 0.00082)	NA	

*Observed (sero)prevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

**Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).

+ Based on the Allan et al. (1990) protocol.

++ no protocol specified (assumed to be the Allan et al. (1990) protocol).

NA = Not applicable.

^aDiagnostic sensitivity and specificity jointly fitted for the Copro-Ag ELISA (Allan et al., 1990) across ageprevalence datasets; model parameters interpreted in terms of representing infection, with infection acquisition (λ_{inf}) and infection loss (ρ_{inf}) rates.

^bBest-fitting model determined by DIC (models jointly fitted to multiple dataset).

^cModel parameters for antibody-based age-seroprevalence data (based on the rES33-immunoblot (Wilkins et al., 1999)), interpreted in terms of exposure, with Ab-seroconversion (λ_{sero}) and Ab-seroreversion (ρ_{sero}) rates.

^dBest-fitting model determined by DIC (models independently fitted to single dataset).

171

172

173 Global human cysticercosis (HCC) antibody seroprevalence

HCC Ab-seroconversion with Ab-seroreversion (reversible model) provided an improved joint fit to 174 175 the multiple datasets based on the antibody lentil lectin-purified glycoprotein enzyme-linked 176 immunoelectrotransfer blot (LLGP-EITB) assay (Tsang et al., 1989) (Table 2 and Figure 3a). These 177 fits were found in the proposed hyperendemic settings ($\geq 6\%$ HCC seroprevalence; with all-age seroprevalence from 12.7% to 24.7%) in Peru (Lescano et al., 2009; Moro et al., 2003), India 178 179 (Jayaraman et al., 2011), and Bali (Theis et al., 1994), and an endemic setting in Brazil (1.6%) 180 (Gomes et al., 2002). For the models jointly fitted to multiple datasets based on the IgG Ab-ELISA 181 (DiagAutom, 2016) hyperendemic setting: all-age seroprevalence from 9.6% to 14.5%) in Nigeria 182 (Edia-Asuke et al., 2015; Weka et al., 2013), and the models independently fitted to the single dataset from Lao PDR (endemic setting: 3.0% all-age seroprevalence) (Holt et al., 2016) based on 183 the rT24H-immunoblot (Hancock et al., 2006), the (simple) model without Ab-seroreversion 184 provided an improved fit (Table 2 and Figure 3b and 3c). Supplementary File 1: Supplementary File 185 186 Table S4 presents all model fits and DIC scores.

187 [Figure 3 here]

188 Figure 3. The relationship between human cysticercosis antibody (Ab)-seroprevalence and human 189 age (in years) for each dataset. Ab-seroconversion (simple) or Ab-seroconversion with Ab-190 seroreversion (reversible) catalytic models (a & b) jointly fitted to multiple datasets (single diagnostic 191 sensitivity and specificity values estimated; dataset-specific λ_{serg} and ρ_{serg} estimates obtained) and (c) 192 models independently fitted to a single dataset, including 95% confidence intervals associated with 193 observed Ab-seroprevalence point estimates. Bayesian Markov chain Monte Carlo methods were used 194 to fit the models to data, with the estimated parameter posterior distributions used to construct 195 predicted (all age) seroprevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-196 fitting models were selected using the deviance information criterion (DIC); both models presented if difference between DIC < 2 (both models have similar support based on the data); a difference > 10 197 198 units indicates that the models are significantly different and therefore only superior fitting model 199 (lowest DIC) is presented). The non-zero predicted seroprevalence at age 0 is due to less than 100% 200 specificity for all tests. The 95% confidence intervals (95% CIs) for age-seroprevalence data-points are 201 calculated by the Clopper-Pearson exact method.

Table 2. Antibody seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antibody) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).

Dataset	All-age observed sero- prevalence (%) (95% CI)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	λ _{sero} = seroconversio n rate, year ⁻¹ (95% BCI)**	ρ _{sero} = seroreversion rate, year ⁻¹ (95% BCI)**
Lescano et al. 2009	y fitted to multip 24.66 (21.59 – 27.94)	Reversible ^b	0.976 (0.937 – 0.994)	/) ^a 0.980 (0.967 – 0.988)	0.12 (0.067 – 0.19)	0.38 (0.21 – 0.62)
Moro et al. 2003	20.82 (16.48 – 25.71)				0.11 (0.0504 – 0.21)	0.501 (0.23 – 0.92)
Jayaraman et al. 2011	15.81 (13.66 – 18.16)				0.019 (0.0095 – 0.093)	0.105 (0.042 – 0.56)
Theis et al. 1994	12.68 (10.48 – 15.16)				0.024 (0.011 – 0.052)	0.16 (0.054 – 0.38)
Gomes et al. 2002	1.64 (0.82 – 2.93)				0.000086 (0.000011 – 0.00066)	0.43 (0.098 – 1.49)
Models jointly	l y fitted to multip	le datasets (Ig	i G Ab-ELISA) ^c	I		1
Edia-Asuke et al. 2015	14.53 (10.72 – 19.06)	Simple ^b	0.872 (0.784 – 0.942)	0.974 (0.916 – 0.998)	0.0044 (0.0018 – 0.0064)	NA

Weka et al.	9.60				0.0023	NA
2013	(5.06 – 16.17)				(0.00053 –	
					0.0046)	
Models independently fitted to an single dataset (rT24H-immunoblot) ^d						
Holt et al.	2.96	Simple ^e	0.964	0.986	0.00044	NA
2016	(1.86 – 4.44)		(0.914 –	(0.969 —	(0.000049 –	
			0.988)	0.997)	0.00090)	

*Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

**Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).

NA = Not applicable.

^aDiagnostic sensitivity and specificity jointly fitted for the LLGP-EITB assay (Tsang et al., 1989) across datasets.

^bBest-fitting model determined by DIC (models jointly fitted to multiple datasets).

^cDiagnostic sensitivity and specificity jointly fitted for the IgG Ab-ELISA

(DiagnosticAutomation/CortezDiagnostic, Inc., 2016) across datasets.

^eBased on the rT24H-immunoblot (Hancock et al., 2006).

^dBest-fitting model determined by DIC (models independently fitted to a single dataset).

203

204 Global human cysticercosis (HCC) antigen seroprevalence

205 HCC infection acquisition with infection loss (reversible model) provided an improved fit for models

fitted jointly to multiple datasets based on B158/B60 Ag-ELISA (Brandt et al., 1992; Dorny et al., 206

207 2000) (Table 3 and Figure 4a), found in one hyperendemic setting (all-age HCC seroprevalence of

208 21.7%) in the DRC (Kanobana et al., 2011), and endemic settings in Zambia (Mwape et al., 2012),

209 Burkina Faso (Sahlu et al., 2019), Lao PDR (Conlan et al., 2012) and Cameroon (Ngeuekam et al.,

- 2003) (all-age HCC seroprevalences from 0.7% to 5.8%). For models fitted to the single dataset 210
- from a hyperendemic setting in Kenya (6.61%) (Wardrop et al., 2015), using the HP10 Ag-ELISA 211
- 212 (Harrison et al., 1989), the (simple) model without infection loss provided an improved fit (Table 3

and Figure 4b). Supplementary File 1: Supplementary File Table S5 presents all model fits and DICscores.

215 [Figure 4 here]

Figure 4. The relationship between human cysticercosis antigen (Ag)-seroprevalence and human age

217 (in years) for each dataset. Infection acquisition (simple) or infection acquisition and loss (reversible) 218 catalytic models (a) jointly fitted to multiple datasets (single diagnostic sensitivity and specificity values 219 estimated; dataset-specific λ_{inf} and ρ_{inf} estimates obtained) and (b) models independently fitted to a 220 single dataset, including 95% confidence intervals associated with observed Ag-seroprevalence point 221 estimates. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the 222 parameter posterior distributions used to construct predicted (all age) seroprevalence curves and 223 associated 95% Bayesian credible intervals (BCIs). Best-fitting model selected by deviance information 224 criterion (DIC); both models presented if difference between DIC < 2 (both models have similar support 225 based on the data); a difference > 10 units indicates that the models are significantly different and 226 therefore only superior fitting model (lowest DIC) is presented). The non-zero predicted seroprevalence 227 at age 0 is due to less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-228 seroprevalence data-points are calculated by the Clopper-Pearson exact method.

Table 3. Antigen seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antigen) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).

Dataset	All-age observed seroprevalen ce (%) (95% Cl)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	λ_{inf} = infection acquisition rate, year ⁻¹ (95% BCI)**	ρ _{inf} = infection loss rate, year ⁻¹ (95% BCI)**
Models jointly	y fitted to multip	le datasets (tl	he B158/B60 A	g-ELISA)ª	I	I
Kanobana et al. 2011	21.66 (19.01 – 24.49)	Reversible ^b	0.909 (0.810 – 0.967)	0.999 (0.995 – 0.999)	0.11 (0.077 – 0.17)	0.330 (0.246 – 0.464)
Mwape et al. 2012	5.79 (4.19 – 7.77)				0.0044 (0.0027 – 0.0088)	0.023 (0.001 – 0.085)
Sahlu et al. 2019	2.45 (1.93 – 3.08)				0.0016 (0.00091 – 0.0032)	0.029 (0.0016 – 0.11)
Conlan et al. 2012	2.22 (1.49 – 3.17)				0.0018 (0.00073 – 0.0034)	0.063 (0.0076 – 0.12)
Nguekam et al. 2003	0.68 (0.47 – 0.95)				0.00017 (0.000077 – 0.00030)	0.004 (0.00018 – 0.026)
Models independently fitted to a single dataset (the HP10 Ag-ELISA) ^c						
Wardrop et al. 2015	6.61 (5.57 – 7.76)	Simple ^d	0.850 (0.735 – 0.927)	0.944 (0.930 – 0.959)	0.00054 (0.000053 – 0.0013)	NA

*Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

**Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI). NA = Not applicable.

^aDiagnostic sensitivity and specificity jointly fitted for the B158/B60 Ag-ELISA (Brandt et al., 1992; Dorny et al., 2000).

^bBest-fitting model determined by DIC (models jointly fitted to multiple datasets).

^cBased on the HP10 Ag-ELISA (Harrison et al., 1989).

^dBest-fitting model determined by DIC (models independently fitted to a single dataset).

230

231

232 Country-wide analysis of human cysticercosis antibody seroprevalence trends in Colombia

233 HCC Ab-seroconversion with Ab-seroreversion (reversible model), fitted to multiple datasets using 234 an IgG Ab-ELISA (López et al. 1988), provided an improved fit across the 23 (out of a total of 24) 235 departments of Colombia (Flórez Sánchez et al., 2013) included in the analysis. Supplementary File 236 1: Supplementary Table S6 presents parameter estimates from the best-fit reversible model by 237 department (parameter estimates for the simple model fits by department can also be found in 238 Supplementary Table S7). Figure 5 presents the best-fit Ab-seroconversion with Ab-seroreversion 239 (reversible) model fit to each age-seroprevalence dataset across departments (Supplementary File 240 1: Supplementary Figure S3 zooms into model fits in medium to lower all-age seroprevalence departments for improved resolution). One department (Bolívar) was omitted due to difficultly 241 242 fitting to such a distinct age-seroprevalence profile (prevalence peak in early ages).

Figure 6 highlights the geographical variation in a) HCC Ab-seroconversion or FoI, b) HCC Abseroreversion rate and c) the HCC antibody all-age seroprevalence, across the 23 departments. In addition, Figure 6 presents substantial geographical variation in risk factors, including: d) the proportion of individuals owning pigs, and e) the proportion of individuals reporting open defecation practices by department (Supplementary File 1: Supplementary Figure S4 highlights variation in the proportion of pigs being kept under free-ranging management practices and the proportion of pigs being kept under free-ranging/mixed practices in those owning pigs (*n*=3,157)).

250 [Figure 5 here]

251 Figure 5. The relationship between human cysticercosis antibody (Ab)-seroprevalence and human 252 age (in years) for 23 departments in Colombia. Each graph shows observed human cysticercosis Ab 253 age-seroprevalence data (black points) and fitted reversible model (Ab-seroconversion with Ab-254 seroreversion; best-fitting model). Y-axis units are from 0-1 (HCC Ab-seroprevalence), with major y-255 axis gridlines at 0, 0.2, 0.4, and 0.6 seroprevalence. X-axis units are from 0-80 years (human age), with 256 major x-axis gridlines at 0, 20, 40, 60 and 80 years of age. Note: Supplementary File 1: Supplementary 257 Figure S7 zooms into predicted plots for a) medium all-age HCC Ab-seroprevalence (6.33–14.37% all-258 age seroprevalence) and b) low all-age HCC Ab-seroprevalence (0.48–4.92% all-age seroprevalence), 259 to view more closely the age-seroprevalence trends and uncertainty around fitted seroprevalence.

260 [Figure 6 here]

Figure 6. Geographic variation in, a) HCC antibody (Ab)-seroconversion rate (λ_{sero} or FoI), and b) HCC 261 262 Ab-seroreversion rate (ρ_{sero}), c) human cysticercosis Ab all-age seroprevalence data, d) pig ownership proportion and e) open defecation reported proportion by department. The FoI (λ_{sero}) and Ab-263 264 services services services are parameter estimates obtained from the best-fit model with HCC Ab-265 seroconversion and Ab-seroreversion (reversible model). Note that San Andrés department is not 266 clearly shown because of its size (small islands located in the top-left of a-c maps). For context, an 267 all-age HCC Ab-seroprevalence = 0.126, HCC Ab-seroconversion rate (Fol or λ_{sero}) = 0.023 year-1, and HCC *Ab*-seroreversion rate (ρ_{sero}) = 0.19 year-1 was obtained in San Andrés 268

269

270 Force-of-infection across settings

A more intuitive approach to understanding the FoI (λ) is to consider its reciprocal, which here corresponds to the average time until humans become Ab-seropositive ($1/\lambda_{sero}$) or infected ($1/\lambda_{inf}$) as inferred through Ag-seropositivity. Equally, the reciprocal of ρ relates to the average duration that humans remain Ab-seropositive ($1/\rho_{sero}$) or infected ($1/\rho_{inf}$). Given the large number of

estimates obtained for HCC, parameter estimates from best-fit models were compared across settings (by all-age (sero)prevalence of each dataset and by country). Figure 7 shows an overall decline in the average time (in years) until humans become HCC Ab-seropositive or infected with increasing all-age HCC (sero)prevalence, noting 18 studies identified in endemic settings (0.48– 5.71% all-age HCC (sero)prevalence), and 19 estimates in hyperendemic settings (6.33–38.68% allage HCC seroprevalence). Within countries, there was significant variation in times until humans become HCC Ab-seropositive or infected (Supplementary File 1: Supplementary Figure S5a).

Figure 7b presents strong evidence for similar average durations of remaining Ab-seropositive (1/ ρ_{sero}) across different endemicity settings and countries (Supplementary File 1: Supplementary Figure S5b). However, there was evidence for a trend of decreasing duration of humans remaining infected (1/ ρ_{inf}) with increasing all-age prevalence (antigen-based studies; n=5).

286 [Figure 7 here]

Figure 7. The relationship between (a) the average time until humans become cysticercosis antibody (Ab)-seropositive or infected ($1/\lambda$) and overall (all-age) seroprevalence, and (b) the average time humans remain cysticercosis Ab seropositive or infected ($1/\rho$) and overall (all-age) seroprevalence. The plot is stratified by proposed endemicity levels defined as endemic (>0% and <6% all-age HCC seroprevalence), and hyperendemic (≥6% all-age HCC seroprevalence).

292

293 Discussion

This paper presents the first global Fol estimates for *T. solium* HTT and HCC, identifying geographical heterogeneity that supports calls to implement both locally-adapted control efforts (Johansen et al., 2017; Gabriël et al., 2017), and setting-specific parameterisations of *T. solium* transmission models to support such efforts (Dixon et al., 2019). We have also placed our HTT Fol estimates in the context of (putative) endemic or hyperendemic settings, with 0.44 per 1,000 people per year

299 for a (single) endemic setting, and from 9.6 to 21 per 1,000 per year for 2 hyperendemic settings. 300 HCC Fol estimates ranged from 0.086 to 21 per 1,000 per year in (18, including Colombian 301 departments) endemic settings (0.086-21 for Ab-based surveys; 0.17-4.4 for Ag-based surveys), 302 and from 0.54–120 per 1,000 per year in (19) hyperendemic settings (2.3–120 for Ab-based surveys; 303 0.54-110 for Ag-based surveys). Further work will be required to refine the proposed (and 304 preliminary) characterisation of endemicity levels, perhaps linked to severity/morbidity (as in other 305 NTDs (Prost et al., 1979; Smith et al., 2013). This will be relevant to inform what constitutes a 306 hyperendemic setting in need of intensified control interventions, as proposed in the WHO 2021-307 2030 goals for *T. solium* (World Health Organization, 2020). Our work also follows the 5 principles 308 distilled by Behrend et al. (2020) for communicating policy-relevant NTD modelling to stakeholders 309 and implementation partners (Supplementary File 1: Supplementary File Table S8).

310 Across epidemiological settings, there was a clear trend of decreasing average time until humans 311 become HCC Ab-seropositive or infected as inferred through Ag-seropositivity (the reciprocal of λ_{sero} or λ_{inf} with increasing all-age seroprevalence. This makes intuitive sense as the FoI increases in 312 313 settings with more intense transmission (reflected by a higher all-age seroprevalence). It was not 314 possible to discern whether such trends exist for HTT given the limited availability of HTT datasets 315 with age-stratified prevalence data. Infection loss with infection acquisition was indicated for two 316 HTT copro-Ag-ELISA-based surveys, and five of six HCC antigen-based surveys, supporting inclusion 317 of parameters representing recovery from HTT and HCC in T. solium transmission models (Dixon et 318 al., 2019). Our infection loss rates for HTT indicate that the duration of adult tapeworm infection 319 (the reciprocal of ρ_{inf}) ranges from 1.3 to 1.4 years (with uncertainty bounds from 1.0 to 2.8 years), 320 aligning with literature estimates suggesting that adult tapeworms live for less than 5 years (Garcia 321 et al., 2014), although our values are only based on two studies. HCC Ab-seroreversion rates (or 322 infection loss rates) from this analysis are also consistently larger than HCC Ab-seroconversion rates 323 (or infection acquisition rates), in agreement with comparisons of HCC Ab-seroreversion to Ab-324 seroconversion (or Ag-seroreversion to Ag-seroconversion) estimates in the literature, which are

generally based on cumulative seroconversion and seroreversion proportions, or rule-based
modelling approaches (Dermauw et al., 2018; Garcia et al., 2001; Coral-Almeida et al., 2015; Mwape
et al., 2013).

328 Some of the modelled estimates presented here indicate large differences between FoI and Ab-329 seroreversion/infection loss rates. These differences are particularly evident in datasets, such as Brazil (Gomes et al., 2002) and Risaralda Department in Colombia (Flórez Sánchez et al., 2013), 330 331 where the reversible model was selected for flat age-(sero)prevalence profiles in low 332 (sero)prevalence settings, where the seroreversion parameter provided minimal information with large uncertainty. The flat age-(sero)prevalence in these settings may also be likely explained by 333 334 false-positives generated given the slightly sub-optimal performance of the serological antibody 335 diagnostic used (e.g. posterior median specificity estimates of 98% in Brazil (Gomes et al., 2002) for 336 the antibody LLGP-EITB test (Tsang et al., 1989), highlighting issues with imperfect specificity of 337 diagnostics in settings with very low transmission intensity.

338 The high cysticercosis Ab-seroreversion rates indicated across datasets are likely indicative of 339 substantial transient responses generated from exposure without establishment of infection. This 340 may also explain the high all-age Ab-seroprevalence estimates observed in field studies (Garcia et 341 al., 2001). Even with Ag-based surveys, a marker of infection rather than exposure, Ag-positivity 342 may still indicate some degree of transient responses due to partial establishment of (immature) 343 cysts or establishment followed by rapid degeneration of (mature) cysts (Mwape et al., 2012). One 344 expectation was that Ab-seroreversion and infection loss rates are fundamentally biological 345 processes so would be fairly consistent across settings. Since Ab-seroreversion or infection loss 346 parameters were allowed to vary among settings, the consistency of the posterior estimates for 347 these parameters indicates that rates of HCC Ab-seroreversion are stable (i.e., no relationship 348 between all-age Ab-seroprevalence and the average duration humans remain Ab-seropositive, 349 Figure 7b; no relationship between the Ab-seroconversion and Ab-seroreversion rates,

350 Supplementary Figure S6), confirming this a priori expectation. The average duration humans 351 remain infected (i.e., the reciprocal of the HCC infection loss rate), however, decreases with 352 increasing seroprevalence (and a positive relationship between infection acquisition rates and 353 infection loss rates, Supplementary Figure S6). Such a signal seen for Ag-based estimates, albeit 354 with only 5 observations, may indicate increased transient responses in higher transmission settings 355 due to more partial establishment of infection. There is however an absence of wider literature to 356 support the hypothesis of exposure intensity affecting probability of successful parasite 357 establishment, but such (transmission intensity-dependent) parasite establishment processed have 358 been incorporated into transmission models for other NTDs (Hamley et al., 2019), highlighting an 359 area of future research with implications for control efforts. In the case of Ab-seroreversion rates, 360 where more data are available compared to infection loss rates, it may be suitable in future work 361 to jointly fit the ρ_{sero} parameter for reversible models across settings.

362 This analysis also provides, for the first time, a detailed country-level analysis, focused on Colombia, exploring the geographical variation of key epidemiological metrics (FoI and antibody 363 364 seroreversion) alongside understanding potential drivers of these trends, using a rich dataset 365 generated by Flórez Sánchez and colleagues (2013). Our results identify substantial subnational variation in HCC FoI (measured by Ab-seroconversion) and Ab-seroreversion rates. There appears 366 367 to be only a limited relationship between these epidemiological quantities, Ab-seroprevalence and 368 other risk factors, including open defecation and pig ownership at the department level, 369 highlighting the complex nature of exposure drivers for HCC. For example, the southeastern rural 370 departments of Vaupés and Amazonas show the highest all-age seroprevalence and FoI estimates. 371 But while Vaupés has one of the highest reported proportions of open defecation, pig ownership is 372 low in both departments. Notwithstanding, substantial subnational variation indicates the need for 373 tailored subnational approaches to control. Spatial variation has been explored formally for this 374 dataset by including spatial structure (i.e., spatial correlation in seropositivity estimated up to 375 approximately 140 km at the Municipality level) into a risk factor analysis, and identifying hot spots

of unexplained residual clustering in northern and southern municipalities in Colombia (Galipó et al., 2021). The findings from this study further supports the requirement for designing subnational and targeted interventions (risk groups such as those with low education levels and displaced persons), alongside the need to understand epidemiological dynamics at the subnational level.

380 A potential limitation of this study is the assumption that diagnostic sensitivity and specificity for a 381 single diagnostic test do not vary substantially among settings (implied by estimating a single 382 posterior for specificity and sensitivity using data from multiple surveys that used the same 383 diagnostic). In reality, there may be some variation in diagnostic performance between settings, 384 particularly for HTT serological diagnostics. For example, the widely used copro-Ag ELISA for 385 detecting adult tapeworm infection is not species specific (Ng-Nguyen et al., 2017). Literature 386 estimates indicate high specificity of HCC diagnostics; however, a proportion of positive results by 387 both HCC Ag- and Ab- diagnostics may be due to transient responses and cross-reactions following 388 exposure to the eggs of other other helminths including Taenia saginata, Echinoccous granulosus 389 and Schistosomia species (Lightowlers et al., 2016b; Noh et al., 2014; Kojic et al., 2003; Furrows et 390 al., 2006). Limited information exists on the co-distribution and prevalence of potentially cross-391 reactive Taenia species (such as Taenia saginata) and other helminths to determine the relative 392 contribution of within- and between-location variability in the performance of specific diagnostic 393 tests.

The prevailing (and most parsimonious) assumption governing the behaviour of the catalytic models fitted in this analysis is of a constant FoI with respect to age. Collated age-(sero)prevalence profiles presented here largely reveal increasing (sero)prevalence with age, or saturation with age through Ab-seroreversion/infection loss, but this behaviour can also be observed with agedependent infection rates (Grenfell and Anderson, 1985). However, the available data limit the testing of more complex FoI functions. A few datasets appeared indeed to deviate from the basic assumption, for example for HTT dynamics in the DRC (Madinga et al., 2017) and Bolívar in Colombia

401 (Flórez Sánchez et al., 2013). While it was not possible to fit the current formulation of catalytic 402 models to these datasets, the specific age-prevalence peaks in younger ages may indicate other 403 drivers such as heterogeneity in exposure (by age) or age-related immunity mechanisms. The 404 observations of HTT copro-Ag-ELISA age-prevalence peaks/odds of infection in children from Peru, 405 Guatemala and Zambia (Garcia et al., 2003a; Allan et al., 1996; Mwape et al., 2015) suggest that 406 these trends might be more widespread. Age peaks in HTT prevalence could indicate the need for 407 targeted mass drug administration (MDA) programmes, such as delivery of anthelminthics 408 (praziquantel) to school-age children, an approach that could be integrated into existing 409 schistosomiasis control programmes where HTT and schistosomiasis are co-endemic. Should more 410 age-prevalence data become available, especially for HTT, fitting models with age-varying FoI may 411 become relevant as indicated in other NTDs (Gambhir et al., 2009).

412 The results presented here, particularly for HCC, where many datasets were available, suggest 413 marked geographical heterogeneity in FoI and associated all-age (sero)prevalence estimates. This 414 indicates substantial variation in the intensity of *T. solium* transmission among endemic settings. 415 There is strong evidence for both HCC Ab-seroreversion and infection loss, likely due to transient 416 dynamics which highlights the need for careful interpretation of cross-sectional (sero)prevalence 417 survey estimates. Catalytic models provide useful tools for interpreting such data, which are far 418 more abundant than a few longitudinal surveys reported in the literature. We also quantify, for the 419 first time, the presence of substantial subnational variation in exposure to HCC, highlighting the 420 need for tailored, sub-national control strategies. More work is also required to understand 421 whether age-prevalence peaks (as observed for HTT) are more commonplace, and whether age-422 targeted control strategies may be required under specific epidemiological and socioeconomic 423 conditions.

424

425 Materials and methods

426 Identifying relevant literature, data sources and data extraction

Published articles with HTT and HCC age-(sero)prevalence *or* age-infection data suitable for constructing age-stratified profiles were identified through two routes. Firstly, by extracting eligible studies from a systematic review of *T. solium* HTT and HCC (sero)prevalence global ranges (Coral-Almeida et al. (2015)), and secondly, by updating the Coral-Almeida et al. (2015) review, using the same strategy (see Supplementary File 1: Supplementary Text S1), for the period 01/11/2014 to 02/10/2019.

433 Sub-national dataset for Colombia

434 Flórez Sánchez et al. (2013) conducted a country-level survey of HCC antibody seroprevalence 435 across 24 of Colombia's 32 administrative departments, sampling 29,360 individuals. Permission 436 was granted from Instituto National de Salud to analyse these data to construct ageseroprevalence profiles. The study collected human cysticercosis Ab-seroprevalence data in the 437 438 period 2008–2010, alongside risk-factor data using a three-stage clustered random sampling 439 framework. To maintain suitable sample sizes for model fitting, age-seroprevalence profiles were 440 constructed at the department level (n = 850-1,291; Supplementary File 1: Supplementary Figure 441 S7), rather than at municipality level (n = 40-1,140). Age-seroprevalence profiles stratified by sex 442 in each department revealed no clear differences (Supplementary File 1: Supplementary Figure S8a), therefore age-seroprevalence data were not stratified by sex for further analysis (but see 443 444 Galipó et al., 2021). Due to difficulty fitting the specific catalytic models to data from the 445 department of Bolívar, only 23 of 24 departments were assessed (n = 28,100).

446 Force-of-infection modelling for human taeniasis and human cysticercosis

The FoI, which describes the average (per capita) rate at which susceptible individuals seroconvert
(become Ab-positive) or become infected, was estimated for HTT and HCC for each dataset. Simple

and reversible catalytic models (Figure 1), originally proposed for fitting to epidemiological data by Muench (1934), were fitted to HTT and HCC age-(sero)prevalence profiles. Model parameters fitted to Ab-datasets were interpreted as Ab-seroconversion (λ_{sero}) and Ab-seroreversion (ρ_{sero}) rates, while (copro-) Ag-datasets were interpreted as infection acquisition (λ_{inf}) and infection loss (ρ_{inf}) rates (Figure 1 provides further details of model structure and parameter interpretation). Like the Fol, the infection loss/ seroreversion parameter (ρ) was also permitted to vary across settings (Dermauw et al., 2018).

456 The true prevalence p(a) at age a is given for the simple model by,

457
$$p(a) = 1 - e^{-\lambda(a)}$$
 [1]

458 and for the reversible model by,

459
$$p(a) = \frac{\lambda}{\lambda + \rho} \left[1 - e^{-(\lambda + \rho)(a)} \right]$$
[2]

460 Model fitting and comparison

Analyses were performed in R version 4.0.5 (2021), following Dixon et al. (2020). A likelihood was constructed assuming that the observed data (representing a binary presence/absence of markers related to exposure or infection) are a realization of an underlying binomial distribution with probability p(a), given by the catalytic model, and adjusted to give the observed prevalence, p'(a), by the sensitivity (se) and specificity (sp) of the diagnostic adopted in the respective datasets (Diggle, 2011),

$$p'(a) = 1 - sp + se + sp - 1 \times p(a)$$
 [3]

Therefore, the likelihood of the data on the number of observed Ab-seropositive or infected humansof age a, r(a), from n(a) humans is,

470
$$L(r, n | \theta) = \Pi_a p'(a)^{r(a)} [1 - p'(a)]^{n(a) - r(a)}$$
 [4]

where θ denotes, generically, the catalytic model (i.e. FoI, seroreversion/infection loss) and diagnostic performance (i.e., sensitivity and specificity) parameters. When the same diagnostic was used across surveys, sensitivity and specificity were assumed to be the same among surveys, yielding a single posterior distribution for the diagnostic performance (sensitivity, specificity) for each test (whilst retaining dataset-specific estimates of λ and ρ). The approach captures uncertainty in diagnostic sensitivity and specificity, but does not permit variation in performance across settings.

A Bayesian Markov chain Monte Carlo (MCMC) Metropolis–Hastings sampling algorithm was implemented to estimate the parameter posterior distribution $f(\theta|r, n)$, assuming uniform prior distributions for λ and ρ (Table 4). A weakly informative prior for λ , assuming a lognormal distribution (mean informed by the median estimate from the simple model fit, and a standard deviation of 1), was used for reversible model fits to prevent λ chains drifting to flat posterior space and failing to converge.

Informative beta distribution priors for the diagnostic sensitivity and specificity were defined to
capture literature estimates of the mean and 95%CIs for these parameters; Supplementary File 1:
Supplementary Table S1, Supplementary Figure S9 and S10 provide more detail).

A maximum of 20,000,000 iterations were run for models fitted simultaneously to multiple datasets (2,000,000 for models fitted to single datasets) to obtain a sufficient sample to reduce autocorrelation through substantial subsampling, with the first 25% of runs being discarded as burn-in. The parameter posterior distributions, used to generate fitted prevalence curves and associated uncertainties for each model fit, were summarised using the median and 95% Bayesian credible intervals (95% BCIs). Simple and reversible model fits were compared using the deviance information criterion (DIC) (Spiegelhalter et al., 2002), with the model producing the smallest DIC score being selected.

494

perpetuity	•
It is made available under a CC-BY	4.0 International license .

T. solium	λ : limits on	ρ: limits on	Rationale
indicator	uniform prior	uniform prior	
	(year ⁻¹)	(year⁻¹)	
HTT (copro-	Minimum: 0	Minimum: 0.333	λ : maximum seroconversion rate of 12 year ⁻¹ = 1
antigen	Maximum: 12	Maximum: 1	month ⁻¹ (1/ λ), representing the lower limit before
(Ag) and			humans become copro-Ag positive (i.e., infected) or
antibody			Ab-seropositive of 1 month
(Ab))			ho: minimum Ab-seroreversion or infection loss rate of
			0.333 year ⁻¹ = 0.0277 month ⁻¹ , or 36-month duration
			(1/ ho) for humans to remain copro-Ag (i.e., infected) or
			Ab- seropositive, reflecting the upper average limit
			assumed for the life- expectancy of adult Taenia solium
			of 3 years (Gonzalez et al., 2002); a maximum of 0.0833
			month ⁻¹ represents the minimum time humans remain
			copro-Ag (i.e., infected) or Ab-seropositive reflecting
			the minimum life-expectancy of the adult worm of 12
			months (Garcia et al., 2003b) (1/ $ ho$)
НСС	Minimum: 0	Minimum: 0	Both λ and ρ : maximum infection acquisition/loss or
(antigen	Maximum: 12	Maximum: 12	Ab-seroconversion / Ab-seroreversion rate of 12 year
and			¹ = 1 month ⁻¹ represents the lower limit before humans
antibody)			acquire infection or become Ab-seropositive (1/ λ), or
			remain HCC antigen (i.e., infected) or Ab-seropositivity
			(1/ρ) of 1 month.

Table 4. Range for force-of-infection (FoI), λ , and seroreversion / infection loss, ρ , uniform priors.

N.B. The reciprocal of the rates of λ and ρ give the duration of susceptibility (1/ λ ; 1/ λ_{sero} for Ab-based, or 1/ λ_{inf} for Ag-based) or of remaining infected or Ab-seropositive ($1/\rho$; $1/\rho_{sero}$ for Ab-based, or $1/\rho_{inf}$ for Ag-based). HTT: human taeniasis; Ab: antibody; Ag: antigen; HCC: human cysticercosis

495

496

498 Acknowledgements: NA

499

- 500 **Competing interests:**
- 501 All authors declare they do not have conflicts of interest.

502

503 Funding statement:

- 504 MAD, PW, CW, ZMC and MGB acknowledge funding from the Medical Research Council (MRC) Centre
- 505 for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK MRC and
- 506 the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat
- 507 agreement and is also part of the European and Developing Countries Clinical Trials Partnership
- 508 (EDCTP2) programme supported by the European Union.

509 Data and code availability:

510 Code to replicate the analysis is provided at https://github.com/mrc-ide/human tsol Fol modelling. 511 All age-(sero)prevalence data available in the following data repository: are http://doi.org/10.14469/hpc/10047. Original data for two datasets available (under the Creative 512 513 Commons Attribution License; CC BY 4.0) from the International Livestock Research Institute openaccess repository (http://data.ilri.org/portal/dataset/ecozd) referenced in Holt et al. (2016) and 514 515 University of Liverpool open-access repository (http://datacat.liverpool.ac.uk/352/) referenced in Fèvre et al. (2017). 516

517 **References**

- Allan JC, Ávila G, Garcia Noval J, Flisser A, Craig PS (1990) Immunodiagnosis of taeniasis by
 coproantigen detection *Parasitology* 101 Pt 3:473–7. doi: 10.1017/s0031182000060686
- 520 Allan JC, Velasquez-Tohom M, Garcia-Noval J, Torres-Alvarez R, Yurrita P, Fletes C, Mata F de, Soto de
- 521 Alfaro H, Craig PS (1996) Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities
- 522 Annals of Tropical Medicine and Parasitology **90(2)**:157–65. doi: 10.1080/00034983.1996.11813039
- 523 Behrend MR, Basáñez MG, Hamley JID, Porco TC, Stolk WA, Walker M, de Vlas SJ; NTD Modelling
- 524 Consortium (2020) Modelling for policy: The five principles of the Neglected Tropical Diseases
- 525 Modelling Consortium PLoS Neglected Tropical Disease 9;14(4):e0008033. doi:
- 526 10.1371/journal.pntd.0008033.
- 527 Braae, U.C., Gabriël, S., Trevisan, C. Thomas LF, Magnussen P, Abela-Ridder B, Ngowi H, Johansen MV
- 528 (2019) Stepwise approach for the control and eventual elimination of *Taenia solium* as a public
- 529 health problem BMC Infectious Diseases 19:182. https://doi.org/10.1186/s12879-019-3812-y.
- 530 Brandt JR, Geerts S, De Deken R, Kumar V, Ceulemans F, Brijs L, Falla N (1992) A monoclonal antibody-
- 531 based ELISA for the detection of circulating excretory-secretory antigens in *Taenia saginata*
- 532 **cysticercosis** International Journal of Parasitology **22**:471–7. doi: 10.1016/0020-7519(92)90148-e
- Conlan J V, Vongxay K, Khamlome B, Dorny P, Sripa B, Elliot A, Blacksell SD, Fenwick S, Thompson RC
 (2012) A cross-sectional study of *Taenia solium* in a multiple taeniid-endemic region reveals
 competition may be protective *American Journal of Tropical Medicine and Hygiene* 87:281–91. doi:
 10.4269/ajtmh.2012.11-0106.
- Coral-Almeida M, Rodríguez-Hidalgo R, Celi-Erazo M, García HH, Rodríguez S, Devleesschauwer B,
 Benítez-Ortiz W, Dorny P, Praet N (2014) Incidence of human *Taenia solium* larval infections in an
 Ecuadorian endemic area: implications for disease burden assessment and control *PLoS Neglected Tropical Diseases* 8: e2887. doi: 10.1371/journal.pntd.0002887

541 Coral-Almeida M, Gabriel S, Abatih EN, Praet N, Benitez W, Dorny P (2015) Taenia solium Human 542 Cysticercosis: A Systematic Review of Sero-epidemiological Data from Endemic Zones around the World PLoS Neglected Tropical Diseases 9:e0003919. doi: 10.1371/journal.pntd.0003919 543 544 CystiTeam Group for Epidemiology and Modelling of Taenia solium Taeniasis/Cysticercosis (2019) The World Health Organization 2030 goals for Taenia solium: Insights and perspectives from 545 transmission dynamics modelling: CystiTeam Group for Epidemiology and Modelling of Taenia 546 547 solium Taeniasis/Cysticercosis Gates Open Research 3:1546. doi: 10.12688/gatesopenres.13068.2. 548 de Coster T, Van Damme I, Baauw J, Gabriël S (2018) Recent advancements in the control of Taenia 549 solium: A systematic review Food and Waterborne Parasitology **13**:e00030. doi: 550 10.1016/j.fawpar.2018.e0003. 551 Dermauw V, Carabin H, Ganaba R, Cissé A, Tarnagda Z, Gabriël S, Dorny P, Millogo A (2018) Factors

Associated with the 18-Month Cumulative Incidence of Seroconversion of Active Infection with Taenia solium Cysticercosis: A Cohort Study among Residents of 60 Villages in Burkina American Journal of Tropical Medicine and Hygiene 99(4):1018-1027. doi: 10.4269/ajtmh.18-0294.

555 DiagAutom. Human Cysticercosis IgG (T. Solium) ELISA Test kit. 2016. Available from:
556 http://www.rapidtest.com/index.php?i=Parasitology-ELISA-kits&id=170&cat=17 [accessed 2020 Mar
557 9].

Diggle P (2011) Estimating Prevalence Using an Imperfect Test Epidemiology Research International.
 doi: 10.1155/2011/608719

Dixon MA, Braae UC, Winskill P, Walker M, Devleesschauwer B, Gabriël S, Basáñez MG (2019)
 Strategies for tackling *Taenia solium* taeniosis/cysticercosis: A systematic review and comparison of
 transmission models, including an assessment of the wider Taeniidae family transmission models
 PLoS Neglected Tropical Diseases 13:e0007301. doi : 10.1371/journal.pntd.0007301.

564	Dixon MA, Winskill P, Harrison WE, Whittaker C, Schmidt V, Sarti E, Bawm S, Dione MM, Thomas LF,
565	Walker M, Basáñez MG (2020) Force-of-infection of Taenia solium porcine cysticercosis: a modelling
566	analysis to assess global incidence and prevalence trends. Scientific Reports 10(1):17637. doi:
567	10.1038/s41598-020-74007-x.

Dixon MA, Winskill P, Harrison WE, Basáñez MG (2021) *Taenia solium* taeniasis/cysticercosis: From
 parasite biology and immunology to diagnosis and control *Advances in Parasitology* 112:133-217.
 doi: 10.1016/bs.apar.2021.03.003.

571 Dorny P, Vercammen F, Brandt J, Vansteenkiste W, Berkvens D, Geerts S (2000) Sero-epidemiological

572 study of Taenia saginata cysticercosis in Belgian cattle Veterinary Parasitology 88:43-9. doi:

573 10.1016/s0304-4017(99)00196-x

Edia-asuke AU, Inabo HI, Mukaratirwa S, Umoh VJ, Whong CMZ, Asuke S, Ella EE (2015) Seroprevalence of human cysticercosis and its associated risk factors among humans in areas of Kaduna metropolis, Nigeria *Journal Infectious Developing Countries* **9**:799–805. doi: 10.3855/jidc.5415

Flórez Sánchez AC, Pastrán SM, Vargas NS, Beltrán M, Enriquez Y, Peña AP, Villarreal A, Salamanca L,
Rincón E, Garzón IP, Muñoz L, Guasmayan L, Valencia C, Parra S, Hernandez N (2013) Cisticercosis en
Colombia. Estudio de seroprevalencia 2008-2010 Acta Neurológica Colombiana 29(2):73–86. ISSN
0120-8748.

Furrows SJ, McCroddan J, Bligh WJ, Chiodini P (2006) Lack of specificity of a single positive 50-kDa
band in the electroimmunotransfer blot (EITB) assay for cysticercosis *Clinical Microbiology and Infection* 12(5):459–62. doi: 10.1111/j.1469-0691.2006.01381.x

Gabriël S, Dorny P, Mwape KE, Trevisan C, Braae UC, Magnussen P, Thys S, Bulaya C, Phiri IK, Sikasunge
CS, Makungu C, Afonso S, Nicolau Q, Johansen MV (2017) Control of Taenia solium

- 587 taeniasis/cysticercosis: The best way forward for sub-Saharan Africa? Acta Tropica 165:252–60. doi:
- 588 10.1016/j.actatropica.2016.04.010.
- 589 Galipó E, Dixon MA, Fronterrè C, Cucunubá ZM, Basáñez MG, Stevens K, Flórez Sánchez AC, Walker M
- 590 (2021) Spatial distribution and risk factors for human cysticercosis in Colombia *Parasites & Vectors*
- **27**;14(1):590. doi: 10.1186/s13071-021-05092-8.
- 592 Gambhir M, Basáñez MG, Burton MJ, Solomon AW, Bailey RL, Holland MJ, Blake IM, Donnelly CA, Jabr
- 593 I, Mabey DC, Grassly NC (2009) The development of an age-structured model for trachoma
- transmission dynamics, pathogenesis and control *PLoS* Neglected Tropical Diseases **3**:e462–e462.
- 595 doi: 10.1371/journal.pntd.0000462.
- 596 Garcia HH, Gonzalez AE, Gilman RH, Palacios LG, Jimenez I, Rodriguez S, Verastegui M, Wilkins P, Tsang
- 597 VC; Cysticercosis Working Group in Peru (2001) Short report: transient antibody response in *Taenia*

598 solium infection in field conditions—a major contributor to high seroprevalence American Journal of

- 599 *Tropical Medicine and Hygiene* **65**:31–32. doi: 10.4269/ajtmh.2001.65.31.
- 600 García H, Gilman R, Gonzalez A, Verastegui M, Rodriguez S, Gadivia C, Tsang VCW, Falcon N, Lescano

AG, Moulton LH, Bernal T, Tovar M, Cysticercosis Working Group in Perú (2003a) Hyperendemic

602 Human and Porcine Taenia Solium Infection in Perú American Journal of Tropical Medicine and

- 603 *Hygiene* **68**:268–75. PMID: 12685628.
- García HH, Gonzalez AE, Evans CAW, Gilman RH, Cysticercosis Working Group in Perú (2003b) *Taenia solium* cysticercosis *Lancet* 362:547–56. doi: 10.1016/S0140-6736(03)14117-7
- García HH, Rodriguez S, Friedland JS Cysticercosis Working Group in Perú (2014) Immunology of
 Taenia solium taeniasis and human cysticercosis *Parasite Immunology* 36(8):388-96. doi:
 10.1111/pim.12126.
- Gomes I, Veiga M, Embiruçu EK, Rabelo R, Mota B, Meza-Lucas A, Tapia-Romero R, Carillo-Becerril BL,
 Alcantara-Anguiano I, Correa D, Melo A (2002) Taeniasis and cysticercosis prevalence in a small

611 village from Northeastern Brazil Arquivos de Neuro-Psiquiatria 60:93–103. doi: 10.1590/s0004-

612 282x2002000200006

613 Gonzalez AE, Gilman R, Garcia H, Lopez T (2002) Use of a simulation model to evaluate control

614 programmes against Taenia solium cysticercosis In: Singh G, Prabhakar S, editors. Taenia solium

615 Cysticercosis From Basic to Clinical Science First. London: CAB International. p. 437–48.

Grenfell BT, Anderson RM (1985) The estimation of age-related rates of infection from case
notifications and serological data The *Journal of Hygiene (London)* 95(2):419-36. doi:
10.1017/s0022172400062859.

Gripper LB, Welburn SC (2017) The causal relationship between neurocysticercosis infection and the
 development of epilepsy—A systematic review *Infect Disease of Poverty* 6:31. doi: 10.1186/s40249-

621 017-0245-у.

622 Hamley JID, Milton P, Walker M, Basáñez MG (2019) Modelling exposure heterogeneity and density

623 dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM:

624 Implications for elimination and data needs *PLoS Neglected Tropical Diseases* **13**(12):e0007557.

625 doi:10.1371/journal.pntd.0007557

626 Hancock K, Pattabhi S, Whitfield FW, Yushak ML, Lane WS, Garcia HH, Gonzalez AE, Gilman RH, Tsang

627 VCW (2006) Characterization and cloning of T24, a *Taenia solium* antigen diagnostic for cysticercosis

628 Molecular and Biochemical Parasitology 147:109–17. doi: 10.1016/j.molbiopara.2006.02.004

Harrison LJS, Joshua GWP, Wright SH, Parjhouse RME (1989) Specific detection of circulating
 surface/secreted glycoproteins of viable cysticerci in *Taenia saginata* cysticercosis *Parasite Immunology* 11:351–70. doi:10.1111/j.1365-3024.1989.tb00673.x

Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, Praet N, Bellinger DC, de Silva NR,
Gargouri N, Speybroeck N, Cawthorne A, Mathers C, Stein C, Angulo FJ, Devleesschauwer B; World
Health Organization Foodborne Disease Burden Epidemiology Reference Group 2010 (2015) World

635 Health Organization Global Estimates and Regional Comparisons of the Burden of Foodborne 636 Disease in 2010 PLoS Medicine 12(12):e1001923. doi: 10.1371/journal.pmed.1001923. 637 Holt HR, Inthavong P, Khamlome B, Blaszak K, Keokamphe C, Somoulay V, Phongmany A, Burr PA, 638 Graham K, Allen J, Donnelly B, Blacksell SD, Unger F, Grace D, Alonso S, Gilbert J (2016) Endemicity of 639 Zoonotic Diseases in Pigs and Humans in Lowland and Upland Lao PDR: Identification of Socio-640 cultural Risk **Factors** PLoS Neglected Tropical Diseases **12**:10(4):e0003913. doi: 641 10.1371/journal.pntd.0003913

Jayaraman T, Prabhakaran V, Babu P, Raghava MV, Rajshekhar V, Dorny P, Muliyil J, Oommen A (2011)

643 Relative seroprevalence of cysticercus antigens and antibodies and antibodies to *Taenia ova* in a

644 **population sample in south India suggests immunity against neurocysticercosis**. *Transactions of The*

645 Royal Society of Tropical Medicine and Hygiene **105**:153–9. doi: 10.1016/j.trstmh.2010.10.007

Johansen MV, Trevisan C, Gabriël S, Magnussen P, Braae UC (2017) Are we ready for *Taenia solium*cysticercosis elimination in sub-Saharan Africa? *Parasitology* 144:59–64. doi:
10.1017/S0031182016000500.

649 Kanobana K, Praet N, Kabwe C, Dorny P, Lukanu P, Madinga J, Mitashi P, Verwijs M, Lutumba P, Olman 650 K (2011) High prevalence of Taenia solium cysticerosis in a village community of Bas-Congo, 651 Democratic Republic of Congo International Journal Parasitology **41**:1015–8. doi: 652 10.1016/j.ijpara.2011.06.004.

Kojic EM, White AC Jr (2003) A positive enzyme-linked immunoelectrotransfer blot assay result for a
 patient without evidence of cysticercosis *Clinical Infectious Diseases* 36(1):e7–9. doi:
 10.1086/344445.

Lescano AG, Garcia HH, Gilman RH, Gavidia CM, Tsang VCW, Rodriguez S, Moulton LH, Villaran MV,
Montano SM, Gonzalez AE (2009) *Taenia solium* Cysticercosis Hotspots Surrounding Tapeworm

658 Carriers: Clustering on Human Seroprevalence but Not on Seizures PLoS Neglected Tropical Diseases

- 659 **3**(1):e371. doi: 10.1371/journal.pntd.0000371
- 660 Lightowlers MW, Donadeu M, Elaiyaraja M, Maithal K, Kumar KA, Gauci CG, Firestone SM, Sarasola P,

Rowan TG (2016a) Anamnestic responses in pigs to the Taenia solium TSOL18 vaccine and

- 662 implications for control strategies *Parasitology* **143**:416–20. doi: 10.1017/S0031182016000202
- 663 Lightowlers MW, Garcia HH, Gauci CG, Donadeu M, Abela-Ridder B (2016b) Monitoring the outcomes

of interventions against *Taenia solium*: options and suggestions *Parasite Immunology* **38**:158–69.

665 doi: 10.1111/pim.12291

López M, Murillo C, Sarria N, Nicholls R, Corredor A (1988) Estandarización y evaluación de la prueba

667 de ELISA para la detección de anticuerpos en LCR y suero en neurocisticercosis *Acta Neurológica*

- 668 *Colombiana* **4**:164–9.
- 669 Madinga J, Kanobana K, Lukanu P, Abatih E, Baloji S, Linsuke S Praet N, Kapinga S, Polman K, Lutumba

670 P, Speybroeck N, Dorny P, Harrison W, Gabriël S (2017) Geospatial and age-related patterns of Taenia

671 solium taeniasis in the rural health zone of Kimpese , Democratic Republic of Congo Acta Tropica

- 672 **165**:100–9. doi:10.1016/j.actatropica.2016.03.013
- Muench H (1943) Derivation of Rates from Summation Data by the Catalytic Curve Journal of the
 American Statistics Association 29:25–38. doi: 10.2307/2278457

675 Moro PL, Lopera L, Bonifacio N, Gilman RH, Silva B, Verastegui M, Gonzalez A, Garcia HH, Cabrera L, Cysticercosis Working Group in Peru (2003) Taenia solium infection in a rural community in the 676 677 Peruvian Andes Parasitology Annals of Tropical Medicine and **97**:373–9. 10.1179/000349803235002371 678

679 Mwape KE, Phiri IK, Praet N, Muma JB, Zulu G, van den Bossche P, de Deken R, Speybroeck N, Dorny

680 P, Gabriël S (2012) *Taenia solium* infections in a rural area of Eastern Zambia-A community based

681 study PLoS Neglected Tropical Diseases 6(3):e1594. doi: 10.1371/journal.pntd.0001594

Mwape KE, Phiri IK, Praet N, Speybroeck N, Muma JB, Dorny P, Gabriël S (2013) The incidence of
 human cysticercosis in a rural community of eastern Zambia *PLoS Neglected Tropical Diseases* 7:
 e2142.

685 Mwape KE, Phiri IK, Praet N, Dorny P, Muma JB, Zulu G, Speybroeck N, Gabriël S (2015) Study and

686 Ranking of Determinants of *Taenia solium* Infections by Classification Tree Models American Journal

687 *of Tropical Medicine and Hygiene* **92**:56–63. doi: 10.4269/ajtmh.13-0593.

688 Ng-Nguyen D, Stevenson MA, Dorny P, Gabriël S, Vo TV, Nguyen VT, Phan TV, Hii SF, Traub RJ (2017)

689 Comparison of a new multiplex real-time PCR with the Kato Katz thick smear and copro-antigen

690 **ELISA for the detection and differentiation of Taenia spp. in human stools** *PLoS Neglected Tropical*

691 *Diseases* **7**;11(7):e0005743.

Nguekam JP, Zoli AP, Zogo PO, Kamga ACT, Speybroeck N, Dorny P, Brandt J, Losson B, Geerts S (2003)
 A seroepidemiological study of human cysticercosis in West Cameroon *Tropical Medicine and*

694 International Health **8**:144–9. doi: 10.1046/j.1365-3156.2003.01000.x.

695 Noh J, Rodriguez S, Lee Y-M, Handali S, Gonzalez AE, Gilman RH, Tsand VCW, Garcia HH, Wilkin PP

696 (2014) Recombinant protein-and synthetic peptide-based immunoblot test for diagnosis of

697 neurocysticercosis Journal of Clinical Microbiology 52(5):1429–34. doi: 10.1128/JCM.03260-13

NTD Modelling Consortium Onchocerciasis Group (2019) The World Health Organization 2030 goals
 for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling
 Consortium Onchocerciasis Group Gates Open Research 26;3:1545. doi:

701 10.12688/gatesopenres.13067.1.

Prost, A., Hervouet, J. P. & Thylefors, B (1979) Les niveaux d'endémicité dans l'onchocercose Bulletin
of the World Health Organization 57, 655–662.

R Core Team (2021). R: A language and environment for statistical computing. R version 4.0.5. R
 Foundation for Statistical Computing, Vienna, Austria. URL : <u>https://www.R-project.org/</u>.

Sahlu I, Carabin H, Ganaba R, Preux PM, Cisse AK, Tarnagda Z, Gabriël S, Dermauw V, Dorny P, Bauer
 C, Milogo A (2019) Estimating the association between being seropositive for cysticercosis and the
 prevalence of epilepsy and severe chronic headaches in 60 villages of rural Burkina Faso *PLoS Nealected Tropical Diseases* 13:e0007101. doi: 10.1371/journal.pntd.0007101

- 710 Smith JL, Flueckiger RM, Hooper PJ, Polack S, Cromwell EA, Palmer SL, Emerson PM, Mabey DCW,
- Solomon AW, Haddad D, Brooker SJ (2013) The geographical distribution and burden of trachoma in
- 712 Africa. *PLoS Neglected Tropical Diseases* **7**: e2359. doi: 10.1371/journal.pntd.0002359.
- 713 Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) Bayesian measures of model complexity
- 714 and fit Journal of the Royal Statistical Society Series B 64, 583–639. doi: 10.1111/1467-9868.00353
- 715 Theis JH, Goldsmith RS, Flisser A, Koss J, Chionino C, Plancarte A (1994) Detection by immunoblot

assay of antibodies to *Taenia solium* cysticerci in sera from residents of rural communities and from

- 717 epileptic patients in Bali, Indonesia The Southeast Asian Journal of Tropical Medicine and Public
- 718 *Health* **25**(3):464-8. PMID: 7777908.
- 719 Thomas LF, Cook EAJ, Fèvre EM, Rushton J (2019) Control of Taenia solium; A Case for Public and
- 720 **Private Sector Investment** *Frontiers in Veterinary Science* **6**:176. doi:10.3389/fvets.2019.00176
- 721 Tsang VC, Brand JA, Boyer AE (1989) An enzyme-linked immunoelectrotransfer blot assay and

722 glycoprotein antigens for diagnosing human cysticercosis (*Taenia solium*) The Journal of Infectious


723 Diseases 159:50–9. doi: 10.1093/infdis/159.1.50

724 Wardrop NA, Thomas LF, Atkinson PM, de Glanville WA, Cook EAJ, Wamae CN, Gabriël S, Dorny P, 725 Harrison LJS, Fèvre EM (2015) The Influence of Socio-economic, Behavioural and Environmental 726 Factors on Taenia spp. Transmission in Western Kenya: Evidence from a Cross-Sectional Survey in 727 Humans Pigs PLoS Neglected 7:9(12):e0004223. doi: and Tropical Diseases 728 10.1371/journal.pntd.0004223.


- 729 Weka RP, Ikeh EI, Kamani J (2013) Seroprevalence of antibodies (IgG) to Taenia solium among pig
- rearers and associated risk factors in Jos metropolis, Nigeria *The Journal of Infection in Developing*
- 731 Countries 15:7(2):67-72. doi: 10.3855/jidc.2309
- 732 Welburn SC, Beange I, Ducrotoy MJ, Okello AL (2015) The neglected zoonoses--the case for integrated
- 733 **control and advocacy** *Clinical Microbiology and Infection* **21**(5):433-43. doi:
- 734 10.1016/j.cmi.2015.04.011.
- 735 Wilkins PP, Allan JC, Verastegui M, Acosta M, Eason AG, Garcia HH, Gonzalez AE, Gilman RH, Tsang VC
- 736 (1999) Development of a serologic assay to detect *Taenia solium* taeniasis *American Journal of*
- 737 *Tropical Medicine and Hygiene* **60**:199–204. doi: 10.4269/ajtmh.1999.60.199
- 738 World Health Organization, 2020 (2020). Ending the Neglect to Attain the Sustainable Development
- 739 **Goals: A Road Map for Neglected Tropical Diseases 2021–2030**. WHO, Geneva, Switzerland, pp. 63.
- 740 Available: <u>https://www.who.int/neglected_diseases/WHONTD-roadmap-2030/en/</u>.

<u>Human taeniasis</u>

a) Simple model (antibody seroconversion or infection acquisition only)




b) Reversible model (antibody seroconversion & seroreversion; or infection acquisition & loss)




Human cysticercosis

c) Simple model (antibody seroconversion; or infection acquistion only) 5 W 415 medRxiv preprint d preprint (which v 10; this version posted February 11, 2022. The copyright holder for this he author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license




 $p(a)=1-e^{-\lambda(a)}$

	Human taeniasis mode	l parameters (a & b)	Human cysticercosis model parameters (c & d)		
	λ (year ⁻¹)	ρ (year ⁻¹)	λ (year ⁻¹)	ρ (year ⁻¹)	
Antibody 🔫	Force of seroconversion (λ_{sero}) : rate at which humans antibody seroconvert, which are raised in serum against <i>T. solium</i> adult tapeworm excretory-secretory (ES) products, indicative of active or past infection (Lightowlers et al., 2016a).	Rate of antibody seroreversion (ρ_{sero}).	Force of seroconversion (λ_{sero}) : rate at which humans antibody seroconvert following exposure to <i>T. solium</i> infective stages (eggs via indirect environmental transmission) and/or infection with <i>T. solium</i> metacestode.	Rate of antibody seroreversion (ρ_{sero}).	
Antigen 🗢	Force of infection acquisition (λ_{inf}): rate at which humans develop an immature/mature adult tapeworm infection indicated by copro- antigen positivity.	Rate at which humans loose adult tapeworm infection indicated by becoming copro-antigen negative ($\boldsymbol{\rho}_{inf}$).	Force of infection acquisition (λ _{inf}): rate at which humans acquire <i>T. solium</i> metacestode infection indicated by antigen positivity.	Rate at which humans clear <i>T. solium</i> metacestode infection, indicating by becoming antigen negative ($\boldsymbol{\rho}_{inf}$).	



a



Model fitted to data — Model with antibody seroconversion

b

